Top Medical News
Stephen Padilla, an hour ago
The risk of heart failure admission to hospital appears to be lower with canagliflozin in direct comparisons with three different classes of nongliflozin diabetes alternatives including DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA) or sulfonylureas, as used in routine care, a recent study suggests. Moreover, the risk of myocardial infarction or stroke is comparable between canagliflozin and nongliflozin antidiabetic drugs.
Yesterday
Global hypomethylation of Alu appears to increasingly influence distant metastatic differentiated thyroid cancer (DTC), poorly (P)DTC and anaplastic (A)TC, according to a recent study. This suggests that the epigenetic entity may be involved in thyroid cancer progression and dedifferentiation.
3 days ago
Risks of infection, but not malignancy, are greater in diabetic than nondiabetic immunosuppressed individuals who underwent renal transplantation and may play a bigger role in the excess mortality populations than previously held, a recent study has found. However, the rate of noncardiovascular death in nondiabetic persons also exceeds cardiovascular deaths.
4 days ago
Long-term treatment with dual-release hydrocortisone (DR-HC) appears to produce favourable effects on insulin secretion and sensitivity in patients with prediabetes, according to a study. The treatment also confers benefits for metabolic and anthropometric parameters.
Roshini Claire Anthony, 4 days ago

Women who breastfed their infants for a longer duration appeared to have a lower risk of diabetes compared with women who did not breastfeed, according to an observational study spanning three decades.

4 days ago
Higher body mass index (BMI) appears to be independently associated with the risk of renal disease among patients with type 2 diabetes, a study has shown.
Roshini Claire Anthony, 5 days ago

Women who undergo a hysterectomy with bilateral ovarian conservation appear to have an elevated risk of cardiovascular (CV) and metabolic disease, particularly those who undergo the procedure at age 35 or younger, a recent study found.

Special Reports
05 Apr 2017
At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
20 Jan 2017
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
04 Jan 2017
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
Pearl Toh, 07 Dec 2016
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Conference Reports
Elvira Manzano, 22 Jan 2018
A reversal of type 2 diabetes (T2D) may be possible with low-calorie liquid diet for up to 5 months, increased physical activity, and cognitive behavioural therapy, preliminary results of the DiRECT* trial has shown.
Audrey Abella, 18 Jan 2018
A titratable, fixed-ratio combination of insulin glargine 100 U/mL and the GLP-1* receptor agonist lixisenatide was associated with favourable glycaemic and gastrointestinal outcomes in patients with type 2 diabetes (T2D), according to several studies presented at IDF 2017.

Roshini Claire Anthony, 17 Jan 2018

Semaglutide has superior efficacy in reducing glucose levels and body weight over a range of comparator treatments, according to findings from the phase 3 SUSTAIN 1–5* trials.

Roshini Claire Anthony, 15 Jan 2018

The cardiovascular (CV) efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes (T2D) appear to be a class effect, according to a systematic review and meta-analysis of four major GLP-1 CV safety trials.

Pearl Toh, 15 Jan 2018
Adding liraglutide treatment to standard of care (SoC) reduced the risk of worsening glycaemic control, along with greater reductions in HbA1c levels in patients with type 2 diabetes (T2D) compared with SoC alone, according to long-term data of the LEADER trial presented at IDF 2017. Risk of amputation also appeared to be lower in liraglutide-treated patients with diabetic foot ulcer (DFU).
Audrey Abella, 12 Jan 2018
Long-term treatment with testosterone undecanoate (TU) in hypogonadal men with type 2 diabetes (T2D) resulted in substantial and sustained weight loss compared with untreated individuals, according to registry studies presented at the IDF 2017.

Elaine Soliven, 12 Jan 2018
Use of metformin during the first trimester of pregnancy showed no significant maternal or foetal adverse outcomes in women with gestational diabetes mellitus (GDM), according to a study presented at IDF 2017.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD